James Dodd

Medical Statistician

I obtained my undergraduate degree in Physics from Durham University in 2000, and have worked in the field of clinical trials since 2008.  In 2014 I obtained an M.Sc. in Quantitative Methods for Science, Social Science and Medicine from Lancaster University.

I worked from 2008-2018 at the Liverpool Cancer Trials Unit (LCTU), based at the University of Liverpool. At the LCTU I worked variously as a data manager, trial coordinator, and statistician in medical statistics. Disease areas of the studies on which I worked included haematological and pancreatic cancer, and chronic non-cancer conditions such as diabetes.

In April 2018 I joined the Tropical Clinical Trials Unit at LSTM as a medical statistician, where I have provided statistical support to clinical trials and studies in a variety of diseases including malaria In pregnancy, diagnostic studies for TB, RSV, sepsis, and administering probiotics to infants to improve gut health.

I also serve on the LSTM Research Ethics Committee (REC) as co-Chairman and provide teaching support for modules in epidemiology and statistics for M.Sc. courses run at LSTM.

Recent publications: 

    Selected publications

    • Madanitsa, M; Barsosio, HC; Minja, DTR;Mtove, G; Kavishe, RA; Dodd, J; et al.Effect of monthly intermittent preventive treatment with dihydroartemisinin–piperaquinewith and without azithromycin versus monthly sulfadoxine–pyrimethamine onadverse pregnancy outcomes in Africa: a double-blind randomised, partlyplacebo-controlled trial 2023 The Lancet Volume 401, p1020-1036 

      Iem,V; Chittamany, P;  Suthepmany, S; Siphanthong, S; Somphavong, S; Kontogianni,K; Dodd, J;  Khan, JAM; Dominguez, J; Wingfield,T; Creswell, J; Cuevas, LEPoolingsputum for Xpert MTB/RIF and Xpert Ultra testing during the Covid-19 pandemicin Lao People’s Democratic Republic PLOS Global Public Health 2(4):e0000116. https://doi.org/10.1371/journal.pgph.0000116 

      Iem V; Chittamany, SS; Siphanthonh, S;Siphanthong, P; Somphavong, S; Kontogianni, K; Dodd, J; Khan, JAM; Dominguez,T; Wingfield, T; Creswell, J; Cuevas, LE;Pooledtesting of sputum with Xpert MTB/RIF and Xpert Ultra during tuberculosis activecase finding campaigns in Lao People’s Democratic Republic BMJ Global Health 022;7:e007592.doi:10.1136/bmjgh-2021-007592 

      Khan UT, Kelly M, Dodd J, et al Roleof MYC and BCL2 expression in a cohort of 43 patients with DLBCL: a retrospective study2020 Journal of Clinical Pathology Published Online doi:10.1136/jclinpath-2020-207121 

      Pettitt, AR; Jackson, R; Cicconi, S;Polydoros, F; Yap, C; Dodd, J; Bickerstaff, M; Stackpoole, M; Khan, UT;Carruthers, S; Lenalidomide,dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocyticleukaemia: final results of the NCRI CLL210 trial. 2020 

      Chew, P G; Frost, F; Mullen, L; Fisher,M; Zadeh, H; Grainger, R; Albouaini, K; Dodd, J; Patel, B; Velavan, P;Adirect comparison of decision rules for early discharge of suspected acutecoronary syndromes in the era of high sensitivity troponin. 2019 European Heart Journal: AcuteCardiovascular Care, Vol 8, No 5 p421-431 

      Wang, Y; Chen, T; Dodd, J; Li, W;Comparison of Clinical Trial Changes in Primary Outcome and Reported Intervention EffectSize Between Trial Registration and Publication 2019 JAMA network open, Vol 2, No 7,e197242 

      Chen, T; Li, C; Qin, R; Wang, Y; Yu, D;Dodd, J; Wang, D; Cornelius, V; AppropriateInterpretation of the Observed NOACs Treatment Effect Size in Real-world Study.2019The American journal of medicine, Vol 132, No2 e752 

      Chen, T; Li, C; Wang, Y; Dodd, J;Cornelius, V; Wang, Duolao; Overestimationof Event Rate and Target Difference among Randomized Clinical in sample sizecalculations Trials: a cross-sectional survey review. 2019 Trials Vol 20 

      Bimba, JS; Lawson, L; Kontogianni, K;Edwards, T; Ekpenyong, BE; Dodd, J; Adams, ER; Sloan, DJ; Creswell, J;Dominguez, J; Prime StoreMTM and OMNIgene Sputum for the Preservation of Sputum for Xpert MTB/RIFTesting in Nigeria.2019 Journal of Clinical Medicine Vol 8, No 12, p2146  

      Pettitt, AR; Polydoros, F; Dodd, J;Oates, M; Lin, K; Kalakonda, N; McCarthy, H; Bloor, A; Schuh, A; Duncombe, A; FinalResults of the Ncri Cll210 Trial of Alemtuzumab, Dexamethasone and Lenalidomidein Patients with High-Risk Cll (Original Protocol). 2016 Haematologica Vol 101, p726 

      Pettitt, AR; Jackson, R; Carruthers, S;Dodd, J; Dodd, S; Oates, M; Johnson, GG; Schuh, A; Matutes, E; Dearden, CE; Alemtuzumabin combination with methylprednisolone is a highly effective induction regimenfor patients with chronic lymphocytic leukemia and deletion of TP53: finalresults of the national cancer research institute CLL206 trial. 2012 Journal of Clinical Oncology Vol30, No 14, p1647-1655 

      Pettitt, R; Matutes, E; Dearden, C;Oscier, D; Carruthers, S; Dodd, J; Dodd, S; Jones, R; Rawstrom, A; Agrawal, S;Resultsof the phase II NCRI CLL206 trial of alemtuzumab in combination with high-dosemethylprednisolone for high-risk (17p-) CLL. 2009 Haematologica Vol 94, p138-139

      Madanitsa, M; Barsosio, HC; Minja, DTR;Mtove, G; Kavishe, RA; Dodd, J; et al.Effectof monthly intermittent preventive treatment with dihydroartemisinin–piperaquinewith and without azithromycin versus monthly sulfadoxine–pyrimethamine onadverse pregnancy outcomes in Africa: a double-blind randomised, partlyplacebo-controlled trial 2023The Lancet Volume 401, p1020-1036 

      Iem,V; Chittamany, P;  Suthepmany, S; Siphanthong, S; Somphavong, S; Kontogianni,K; Dodd, J;  Khan, JAM; Dominguez, J; Wingfield,T; Creswell, J; Cuevas, LEPoolingsputum for Xpert MTB/RIF and Xpert Ultra testing during the Covid-19 pandemicin Lao People’s Democratic Republic PLOS Global Public Health 2(4):e0000116. https://doi.org/10.1371/journal.pgph.0000116 

      Iem V; Chittamany, SS; Siphanthonh, S;Siphanthong, P; Somphavong, S; Kontogianni, K; Dodd, J; Khan, JAM; Dominguez,T; Wingfield, T; Creswell, J; Cuevas, LE;Pooledtesting of sputum with Xpert MTB/RIF and Xpert Ultra during tuberculosis activecase finding campaigns in Lao People’s Democratic Republic BMJ Global Health 022;7:e007592.doi:10.1136/bmjgh-2021-007592 

      Khan UT, Kelly M, Dodd J, et al Roleof MYC and BCL2 expression in a cohort of 43 patients with DLBCL: a retrospective study2020 Journal of Clinical Pathology Published Online doi:10.1136/jclinpath-2020-207121 

      Pettitt, AR; Jackson, R; Cicconi, S;Polydoros, F; Yap, C; Dodd, J; Bickerstaff, M; Stackpoole, M; Khan, UT;Carruthers, S; Lenalidomide,dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocyticleukaemia: final results of the NCRI CLL210 trial. 2020 

      Chew, P G; Frost, F; Mullen, L; Fisher,M; Zadeh, H; Grainger, R; Albouaini, K; Dodd, J; Patel, B; Velavan, P; Adirect comparison of decision rules for early discharge of suspected acutecoronary syndromes in the era of high sensitivity troponin. 2019 European Heart Journal: Acute Cardiovascular Care, Vol 8, No 5 p421-431 

      Wang, Y; Chen, T; Dodd, J; Li, W;Comparisonof Clinical Trial Changes in Primary Outcome and Reported Intervention EffectSize Between Trial Registration and Publication 2019 JAMA network open, Vol 2, No 7,e197242 

      Chen, T; Li, C; Qin, R; Wang, Y; Yu, D;Dodd, J; Wang, D; Cornelius, V; AppropriateInterpretation of the Observed NOACs Treatment Effect Size in Real-world Study.2019The American journal of medicine, Vol 132, No2 e752 

      Chen, T; Li, C; Wang, Y; Dodd, J;Cornelius, V; Wang, Duolao; Overestimationof Event Rate and Target Difference among Randomized Clinical in sample sizecalculations Trials: a cross-sectional survey review. 2019 Trials Vol 20 

      Bimba, JS; Lawson, L; Kontogianni, K;Edwards, T; Ekpenyong, BE; Dodd, J; Adams, ER; Sloan, DJ; Creswell, J;Dominguez, J; PrimeStoreMTM and OMNIgene Sputum for the Preservation of Sputum for Xpert MTB/RIFTesting in Nigeria.2019 Journal of Clinical Medicine Vol 8, No 12, p2146  

      Pettitt, AR; Polydoros, F; Dodd, J;Oates, M; Lin, K; Kalakonda, N; McCarthy, H; Bloor, A; Schuh, A; Duncombe, A; FinalResults of the Ncri Cll210 Trial of Alemtuzumab, Dexamethasone and Lenalidomidein Patients with High-Risk Cll (Original Protocol). 2016 Haematologica Vol 101, p726 

      Pettitt, AR; Jackson, R; Carruthers, S;Dodd, J; Dodd, S; Oates, M; Johnson, GG; Schuh, A; Matutes, E; Dearden, CE; Alemtuzumabin combination with methylprednisolone is a highly effective induction regimenfor patients with chronic lymphocytic leukemia and deletion of TP53: finalresults of the national cancer research institute CLL206 trial. 2012 Journal of Clinical Oncology Vol30, No 14, p1647-1655 

      Pettitt, R; Matutes, E; Dearden, C;Oscier, D; Carruthers, S; Dodd, J; Dodd, S; Jones, R; Rawstrom, A; Agrawal, S; Resultsof the phase II NCRI CLL206 trial of alemtuzumab in combination with high-dosemethylprednisolone for high-risk (17p-) CLL. 2009 Haematologica Vol 94, p138-139